MARKET

MGEN

MGEN

Miragen Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9870
-0.1630
-14.17%
After Hours: 0.9900 +0.003 +0.30% 19:50 05/29 EDT
OPEN
1.100
PREV CLOSE
1.150
HIGH
1.100
LOW
0.9000
VOLUME
3.68M
TURNOVER
--
52 WEEK HIGH
2.580
52 WEEK LOW
0.3110
MARKET CAP
52.39M
P/E (TTM)
-0.8675
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MGEN stock price target is 4.200 with a high estimate of 6.00 and a low estimate of 1.000.

EPS

MGEN News

More
ZS, AGEN, CGC and MGNX among midday movers
Seeking Alpha - Article · 1d ago
CGC, DXC among premarket losers
Seeking Alpha - Article · 1d ago
3 Strong Buy Biotech Stocks Under $5 With Explosive Upside Potential
TipRanks · 3d ago
miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference
BOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and
GlobeNewswire · 4d ago
Did Changing Sentiment Drive Miragen Therapeutics' (NASDAQ:MGEN) Share Price Down A Painful 94%?
Simply Wall St. · 05/12 13:49
Miragen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 04:08
Miragen Therapeutics EPS beats by $0.03, beats on revenue
Miragen Therapeutics (NASDAQ:MGEN): Q1 GAAP EPS of -$0.18 beats by $0.03. Revenue of $0.83M (+124.3% Y/Y) beats by $0.24M. Press Release
seekingalpha · 05/08 01:16
miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 05/07 21:05

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About MGEN

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
More

Webull offers kinds of Miragen Therapeutics Inc stock information, including NASDAQ:MGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGEN stock news, and many more online research tools to help you make informed decisions.